Intrinsic Value of S&P & Nasdaq Contact Us

XOMA Corporation XOMAO NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
66/100
3/7 Pass
SharesGrow Intrinsic Value
$14.46
-43.5%

XOMA Corporation (XOMAO) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 6 Buy, 4 Hold.

Analysts estimate Earnings Per Share (EPS) of $-1.08 and revenue of $0.03B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-0.71 vs est $-1.08 (beat +34.2%). 2025: actual $1.53 vs est $1.17 (beat +31.3%). Analyst accuracy: 62%.

XOMAO Analyst Ratings

Buy
10
Ratings
6 Buy
4 Hold
Based on 10 analysts giving stock ratings to XOMA Corporation in the past 3 months
Rating breakdown
Buy
6 60%
Hold
4 40%
60%
Buy
6 analysts
40%
Hold
4 analysts
0%
Sell
0 analysts

EPS Estimates — XOMAO

62%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024 Actual –$0.71 vs Est –$1.08 ▲ 52.0% off
2025 Actual $1.53 vs Est $1.17 ▲ 23.8% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.

Revenue Estimates — XOMAO

97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $0.028B vs Est $0.029B ▼ 0.1% off
2025 Actual $0.052B vs Est $0.049B ▲ 5.2% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message